Skip to main content
Fig. 6 | Journal of Hematology & Oncology

Fig. 6

From: Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer

Fig. 6

Effect of inhibition of DOT1L pharmacologically on tumor progression in vivo. After orthotopic transplantation of tumors performed by SK-OV-3 cells transduced with CMV-Fluc-IRES-RFP lentiviral particles, BALB/c-nude mice were treated with SGC0946 (10 mg/kg body weight) or vehicle control twice a week for 6 weeks by intraperitoneal injection. The size of tumor was closely monitored by three-dimensional reconstruction of in vivo bioluminescence images. a The representative images (left) were shown and tumor size (right) was calculated (n = 9 per group, P < 0.05, Student’s t test, data represented as mean±SD). b The mice were sacrificed after being monitored using the IVIS SPECTRUM system. Photograph of tumor masses (left) was shown and the tumor weight (right) was measured (n = 9 per group, P < 0.05, Student’s t test, data represented as mean±SD). RT-PCR was performed on the tumor masses from the mice mentioned above to analyze the expression of CDK6 (c) and CCND3 (d). GAPDH was used as a loading control. e Representative IHC images for H3K79me2, CDK6, and cyclin D3 in the mice were shown. f The positive cells of H3K79me2, CDK6, and cyclin D3 were measured

Back to article page